A lymphoma drug may be used to treat brain cancer

, a targeted drug used to treat lymphoma and leukemia, may be used to treat a common and deadly brain cancer, glioma, according to a study published in the latest issue of the American journal
.
, a scientist at the Lerner Institute at the Cleveland Clinic, told Xinhua that animal experiments have found that erudinib prolongs survival in mice with glioma, extending survival by about 10 times compared to the chemotherapy drug methamphetamine, which is commonly used to treat gliomas.
study also found that irudinib was better associated with radiotherapy than errutinib or radiotherapy alone.the
Bowsden team previously found that a protein in GCH stem cells, the X chromosome myeloid tyrosine kinase (BMX), increased levels, activating signal transduction and transcription activation factor 3 (STAT3), which is associated with the malignant proliferation of glioma stem cells. New research has found that errutinic inhibits both proteins, thereby inhibiting the proliferation of glioma stem cells.
, the survival rate of patients with glioma is not high, and the median survival after standard treatment is less than 15 months.
U.S. Food and Drug Administration has previously approved errutinie for the treatment of certain types of cancers such as lymphoma and leukemia. The effects of errutini on patients with gliomas need to be further tested, but the use of drugs approved by the FDA could skip lengthy safety studies and could soon enter clinical trials, Bosden said. (Source: Xinhua News Agency Zhou Zhou)